Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?

David Zaenger, Bryan M. Rabatic, Byron Dasher, Waleed F. Mourad

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction Male breast cancer (MBC) is a rare disease and lacks data-based treatment guidelines. Most men are currently treated with modified radical mastectomy (MRM) or simple mastectomy (SM). We compared the oncologic treatment outcomes of early-stage MBC to determine whether breast conservation therapy (BCT) is appropriate. Materials and Methods We searched the Surveillance, Epidemiology, and End Results database for MBC cases. That cohort was narrowed to cases of stage I-II, T1-T2N0 MBC with surgical and radiation therapy (RT) data available. The patients had undergone MRM, SM, or breast conservation surgery (BCS) with or without postoperative RT. We calculated the actuarial 5-year cause-specific survival (CSS). Results We identified 6263 MBC cases and included 1777 men with stage I or II, T1-T2, node-negative disease, who had the required treatment information available. MRM without RT was the most common treatment (43%). Only 17% underwent BCS. Of the BCS patients, 46% received adjuvant RT to complete the traditional BCT. No deaths were recorded in the BCT group, regardless of stage, or in the 3 stage I surgical groups if the men had received RT. The actuarial 5-year CSS was 100% in each BCT group. MRM alone resulted in an actuarial 5-year CSS of 97.3% for stage 1% and 91.2% for stage 2. Conclusion The results from our study suggest that BCT for early-stage MBC yields comparable survival compared with more invasive treatment modalities (ie, MRM or SM alone). This could shift the treatment paradigm to less-invasive interventions and might have the added benefit of increased functional and psychological outcomes. Further prospective studies are needed to confirm our conclusions.

Original languageEnglish (US)
Pages (from-to)101-104
Number of pages4
JournalClinical Breast Cancer
Volume16
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Male Breast Neoplasms
Modified Radical Mastectomy
Segmental Mastectomy
Breast
Simple Mastectomy
Radiotherapy
Survival
Therapeutics
Rare Diseases
Epidemiology
Databases
Prospective Studies
Guidelines
Psychology

Keywords

  • Breast conservation therapy
  • Postoperative radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? / Zaenger, David; Rabatic, Bryan M.; Dasher, Byron; Mourad, Waleed F.

In: Clinical Breast Cancer, Vol. 16, No. 2, 01.04.2016, p. 101-104.

Research output: Contribution to journalArticle

Zaenger, David ; Rabatic, Bryan M. ; Dasher, Byron ; Mourad, Waleed F. / Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?. In: Clinical Breast Cancer. 2016 ; Vol. 16, No. 2. pp. 101-104.
@article{d2b08192a20247bb92db87c6e561c461,
title = "Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?",
abstract = "Introduction Male breast cancer (MBC) is a rare disease and lacks data-based treatment guidelines. Most men are currently treated with modified radical mastectomy (MRM) or simple mastectomy (SM). We compared the oncologic treatment outcomes of early-stage MBC to determine whether breast conservation therapy (BCT) is appropriate. Materials and Methods We searched the Surveillance, Epidemiology, and End Results database for MBC cases. That cohort was narrowed to cases of stage I-II, T1-T2N0 MBC with surgical and radiation therapy (RT) data available. The patients had undergone MRM, SM, or breast conservation surgery (BCS) with or without postoperative RT. We calculated the actuarial 5-year cause-specific survival (CSS). Results We identified 6263 MBC cases and included 1777 men with stage I or II, T1-T2, node-negative disease, who had the required treatment information available. MRM without RT was the most common treatment (43{\%}). Only 17{\%} underwent BCS. Of the BCS patients, 46{\%} received adjuvant RT to complete the traditional BCT. No deaths were recorded in the BCT group, regardless of stage, or in the 3 stage I surgical groups if the men had received RT. The actuarial 5-year CSS was 100{\%} in each BCT group. MRM alone resulted in an actuarial 5-year CSS of 97.3{\%} for stage 1{\%} and 91.2{\%} for stage 2. Conclusion The results from our study suggest that BCT for early-stage MBC yields comparable survival compared with more invasive treatment modalities (ie, MRM or SM alone). This could shift the treatment paradigm to less-invasive interventions and might have the added benefit of increased functional and psychological outcomes. Further prospective studies are needed to confirm our conclusions.",
keywords = "Breast conservation therapy, Postoperative radiation therapy",
author = "David Zaenger and Rabatic, {Bryan M.} and Byron Dasher and Mourad, {Waleed F.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.clbc.2015.11.005",
language = "English (US)",
volume = "16",
pages = "101--104",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?

AU - Zaenger, David

AU - Rabatic, Bryan M.

AU - Dasher, Byron

AU - Mourad, Waleed F.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Introduction Male breast cancer (MBC) is a rare disease and lacks data-based treatment guidelines. Most men are currently treated with modified radical mastectomy (MRM) or simple mastectomy (SM). We compared the oncologic treatment outcomes of early-stage MBC to determine whether breast conservation therapy (BCT) is appropriate. Materials and Methods We searched the Surveillance, Epidemiology, and End Results database for MBC cases. That cohort was narrowed to cases of stage I-II, T1-T2N0 MBC with surgical and radiation therapy (RT) data available. The patients had undergone MRM, SM, or breast conservation surgery (BCS) with or without postoperative RT. We calculated the actuarial 5-year cause-specific survival (CSS). Results We identified 6263 MBC cases and included 1777 men with stage I or II, T1-T2, node-negative disease, who had the required treatment information available. MRM without RT was the most common treatment (43%). Only 17% underwent BCS. Of the BCS patients, 46% received adjuvant RT to complete the traditional BCT. No deaths were recorded in the BCT group, regardless of stage, or in the 3 stage I surgical groups if the men had received RT. The actuarial 5-year CSS was 100% in each BCT group. MRM alone resulted in an actuarial 5-year CSS of 97.3% for stage 1% and 91.2% for stage 2. Conclusion The results from our study suggest that BCT for early-stage MBC yields comparable survival compared with more invasive treatment modalities (ie, MRM or SM alone). This could shift the treatment paradigm to less-invasive interventions and might have the added benefit of increased functional and psychological outcomes. Further prospective studies are needed to confirm our conclusions.

AB - Introduction Male breast cancer (MBC) is a rare disease and lacks data-based treatment guidelines. Most men are currently treated with modified radical mastectomy (MRM) or simple mastectomy (SM). We compared the oncologic treatment outcomes of early-stage MBC to determine whether breast conservation therapy (BCT) is appropriate. Materials and Methods We searched the Surveillance, Epidemiology, and End Results database for MBC cases. That cohort was narrowed to cases of stage I-II, T1-T2N0 MBC with surgical and radiation therapy (RT) data available. The patients had undergone MRM, SM, or breast conservation surgery (BCS) with or without postoperative RT. We calculated the actuarial 5-year cause-specific survival (CSS). Results We identified 6263 MBC cases and included 1777 men with stage I or II, T1-T2, node-negative disease, who had the required treatment information available. MRM without RT was the most common treatment (43%). Only 17% underwent BCS. Of the BCS patients, 46% received adjuvant RT to complete the traditional BCT. No deaths were recorded in the BCT group, regardless of stage, or in the 3 stage I surgical groups if the men had received RT. The actuarial 5-year CSS was 100% in each BCT group. MRM alone resulted in an actuarial 5-year CSS of 97.3% for stage 1% and 91.2% for stage 2. Conclusion The results from our study suggest that BCT for early-stage MBC yields comparable survival compared with more invasive treatment modalities (ie, MRM or SM alone). This could shift the treatment paradigm to less-invasive interventions and might have the added benefit of increased functional and psychological outcomes. Further prospective studies are needed to confirm our conclusions.

KW - Breast conservation therapy

KW - Postoperative radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84960250387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960250387&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2015.11.005

DO - 10.1016/j.clbc.2015.11.005

M3 - Article

C2 - 26718092

AN - SCOPUS:84960250387

VL - 16

SP - 101

EP - 104

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -